Abstract
Several plasma components, such as complement (C) components, play a role in the clearance of liposomes from the circulation. The interactions between liposomes and the C system were investigated in this study. Multilamellar vesicle (MLV) liposomes, which were damaged by activation of the complement, became susceptible depending on the density of cetylmannoside (Man) on the liposome membrane, and activation proceeded through the alternative C pathway as observed for liposomes without Man (PC-MLV) (K. Funato et al, Biochim. Biophys. Acta 1103:198–204, 1992). In addition, the capacity of Man-modified liposomes (Man-MLV) to activate the alternative C pathway was abolished by preadsorption of plasma with Man-MLV but not with PC-MLV. The results suggest that a specific plasma factor adsorbed with Man-MLV was responsible for the augmentation of the C activation and, further, that the rapid clearance of Man-MLV from the circulation is caused by both enhanced C-mediated liposome permeability and enhanced C-mediated phagocytosis of liposomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. Harish and P. D. Patel. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:39–90 (1992).
R. L. Juliano and G. Lin. The interaction of plasma proteins with liposomes: Protein binding and effects on the clotting and complement system. In B. H. Tom and H. R. Six (eds.), Liposomes and Immunobiology, Elsevier Science, Amsterdam, 1980, pp. 49–66.
F. Bonte and R. L. Juliano. Interaction of liposomes with serum proteins. Chem. Phys. Lipids 40:359–372 (1986).
A. Chonn, S. C. Semple, and P. R. Cullis. Association of blood proteins with large unilamellar liposomes in vivo: Relation to circulation lifetimes. J. Biol. Chem. 267:18759–18765 (1990).
K. Funato, Y. Ritsuko, and H. Kiwada. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim. Biophys. Acta 1103:198–204 (1992).
H. Harashima, K. Sakata, K. Funato, and H. Kiwada. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm. Res. 11:402–406 (1993).
P. K. Das, G. J. Murray, G. C. Zirzow, R. O. Brady, and J. A. Barranger. Lectin-specific targeting of β-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem. Med. 33:124–131 (1985).
P. Ghosh and B. K. Bachhawat. Grafting of different glycosides on the surface of liposomes and its effect on the tissue distribution of 125I-labelled γ-globulin encapsulated in liposomes. Biochim. Biophys. Acta 632:562–572 (1980).
C. D. Muller and F. Schuber. Neo-mannosylated liposomes: Synthesis and interaction with mouse Kupffer cells and resident perioneal macrophages. Biochim. Biophys. Acta 986:97–105 (1989).
G. Barratt, J.-P. Tenu, A. Yapo, and J.-F. Petit. Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochem. Biophys. Acta 862:153–164 (1986).
C. Yamashita, H. Matsuo, K. Akiyama, and K. Kiwada. Enhancing effect of cetylmannoside on targeting of liposomes to kupffer cells in rats. Int. J. Pharm. 70:225–233 (1991).
H. Kiwada, H. Nimura, Y. Fujisaki, S. Yamada, and Y. Kato. Application of synthetic alkyl glycoside vesicles as drug carriers. I. Preparation and physical properties. Chem. Pharm. Bull. 33:753–759 (1985).
S. Tanaka, F. Kitamura, and T. Suzuki. Studies on the hemolytic activity of the classical and alternative pathway of complement in various animal species. Complement 4:33–41 (1987).
W. Miyazaki, H. Tamaoka, M. Shinohara, H. Kaise, T. Izawa, Y. Nakano, T. Kinoshita, K. Hong, and K. Inoue. A complement inhibitor produced by Stachybotrys complementi, nov. sp. K-76, a new species of fungi imperfecti. Microbiol. Immunol. 24:1091–1108 (1980).
D. P. Fine, S. R. Marney, D. G. Colley, Jr., J. S. Sergent, and R. M. D. Prez. C3 shunt activation in human serum chelated with EGTA. J. Immunol. 109:807–809 (1972).
C. Mold and H. Gewurz. Activation of human complement by liposomes: Serum factor requirement for alternative pathway activation. J. Immunol. 125:696–700 (1980).
I. Ihara, Y. Harada, S. Ihara, and M. Kawakami. A new complement-dependent bactericidal factor found in nonimmune mouse sera: Specific binding to polysaccharide of Ra chemotype salmonella. J. Immunol. 128:1256–1260 (1982).
J. E. Schweinle, R. A. B. Ezekowitz, A. J. Tenner, M. Kuhlman, and K. A. Joiner. Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of salmonella. J. Clin. Invest. 84:1821–1829 (1989).
M. A. Wilson and T. R. Kozel. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 60:754–761 (1992).
H. A. Schenkein and S. Ruddy. The role of immunoglobulins in alternative complement pathway activation by zymosan. J. Immunol. 126:7–10 (1981).
K. Ikeda, T. Sannoh, N. Kawasaki, T. Kawasaki, and I. Yamashina. Serum lectin with known structure activates complement through the classical pathway. J. Biol. Chem. 262:7451–7454 (1987).
Y.-H. Ji, M. Matsushita, H. Okada, T. Fujita, and M. Kawakami. The C4 and C2 but not C1 components of complement are responsible for the complement activation triggered by the Ra-reactive factor. J. Immunol. 141:4271–4275 (1988).
M. Ohta, M. Okada, I. Yamashina, and T. Kawasaki. The mechanism of carbohydrate-mediated complement activation by the serum mannan-binding protein. J. Biol. Chem. 265:1980–1984 (1990).
M. Matsushita, A. Takahashi, H. Hatsuse, M. Kawakami, and T. Fujita. Human mannose-binding protein is identical to a component of Ra-reactive factor. Biochem. Biophys. Res. Commun. 183:645–651 (1992).
S. Inai, K. Nagaki, S. Ebisu, K. Kato, S. Kotani, and A. Misaki. Activation of the alternative complement pathway by water-insoluble glucans of streptococcus mutans: The relation between their chemical structures and activating potencies. J. Immunol. 117:1256–1260 (1976).
R. L. Richards, H. Gewurz, J. Siegel, and C. R. Alving. Interactions of C-reactive protein and complement with liposomes. J. Immunol. 122:1185–1189 (1979).
C. R. Alving, R. L. Richards, and A. A. Guirguis. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J. Immunol. 118:342–347 (1977).
P. S. Seifert and M. D. Kazatchkine. Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol. Immun. 24:1303–1308 (1987).
A. S. D. Pang, A. Katz, and J. O. Minta. C3 deposition in cholesterol-induced atherosclerosis in rabbits: A possible etiologic role for complement in atherogenesis. J. Immunol. 123:1117–1122 (1979).
C. R. Alving and G. M. Swartz, Jr. Antibodies to cholesterol, cholesterol conjugates, and liposomes: Implications for atherosclerosis and autoimmunity. Crit. Rev. Immunol. 10:441–453 (1991).
H. Kiwada, T. Miyajima, and Y, Kato. Studies on the uptake mechanism of liposomes by perfused rat liver. II. An indispensable factor for liver uptake in serum. Chem. Pharm. Bull. 35:1189–1195 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Funato, K., Yamashita, C., Kamada, J. et al. Plasma Factor Triggering Alternative Complement Pathway Activation by Liposomes. Pharm Res 11, 372–376 (1994). https://doi.org/10.1023/A:1018952718496
Issue Date:
DOI: https://doi.org/10.1023/A:1018952718496